Development of novel decoy oligonucleotides: Advantages of circular dumb-bell decoy

Current Opinion in Molecular Therapeutics

Volumn 5, Issue 2, 2003, Pages 107-112

  Tomita, Naruya ^a   Tomita, Tetsuya ^a   Yuyama, Kazuhiko ^b   Tougan, Takahiro ^b   Tajima, Tsuyoshi ^b   Ogihara, Toshio ^a   Morishita, Ryuichi ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b GeneDesign Inc   (Japan)

Author keywords

E2F; Gene therapy; NF B; Transcription factor decoy

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; DNA BINDING PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NUCLEASE; PHOSPHODIESTERASE; REGULATOR PROTEIN; TRANSCRIPTION FACTOR E2F;

CLINICAL TRIAL; DRUG BINDING; DRUG DEGRADATION; ENHANCER REGION; GENE CONTROL; GENE EXPRESSION REGULATION; GENE TARGETING; GLOMERULONEPHRITIS; HEART INFARCTION; HUMAN; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; NONVIRAL GENE THERAPY; PROMOTER REGION; REPERFUSION INJURY; RESTENOSIS; REVIEW; RHEUMATOID ARTHRITIS; TRANSCRIPTION REGULATION;

ARTHRITIS, RHEUMATOID; CORONARY RESTENOSIS; GENE THERAPY; GLOMERULONEPHRITIS; HUMANS; OLIGONUCLEOTIDES; TRANS-ACTIVATORS;

ANIMALIA;

EID: 0038814156     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (51)

1. Tomita N, Morishita R, Higaki J, Ogihara T: A novel strategy for gene therapy and gene regulation analysis using transcription factor decoy oligonucleotides. Exp Nephrol (1997) 5(5):429-434.
2. Morishita R, Higaki J, Tomita N, Ogihara T: Application of transcription factor "decoy" strategy as means of gene therapy and study of gene expression in cardiovascular disease. Circ Res (1998) 82(10):1023-1028.
3. Morishita R, Nakagami H, Taniyama Y, Matsushita H, Yamamoto K, Tomita N, Moriguchi A, Matsumoto K, Higaki J, Ogihara T: Oligonucleotide-based gone therapy for cardiovascular disease. Clin Chem Lab Med (1998) 36(8):529-534.
4. Morishita R, Aoki M, Kaneda Y: Oligonucleotide-based gem therapy for cardiovascular disease: Are oligonucleotide, therapeutics novel cardiovascular drugs? Curr Drug Targets (2000) 1(1):15-23.
5. Tomita N, Morishita R, Tomita T, Ogihara T: Potential therapeutic applications of decoy oligonucleotides. Curr Opin Mol Ther (2002) 4(2):166-170.
6. Tomita N, Morishita R, Tomita T, Azauma H, Ogihara T: NFκB as a therapeutic target for transcription factor decoy strategy in inflammatory diseases. Curr Med Chem (2003) 2:1-6.
7. Morishita R, Gibbons GH, Horiuchi M, Ellison KE, Nakajima M, Zhang L, Kaneda Y, Ogihara T, Dzau VJ: A gene therapy strategy using a transcription factor decoy of the E2F binding site inhibits smooth muscle proliferation in vivo. Proc Natl Acad Sci USA (1995) 92(13):5855-5859.
8. Morishita R, Higaki J, Tomita N, Aoki M, Moriguchi A, Tamura K, Murakami K, Kaneda Y, Ogihara T: Role of transcriptional cis-elements, angiotensinogen gene-activating elements, of angiotensinogen gene in blood pressure regulation. Hypertension (1996) 27(3 Pt 2):502-507.
9. Morishita R, Sugimoto T, Aoki M, Kida I, Tomita N, Moriguchi A, Maeda K, Sawa Y, Kaneda Y, Higaki J, Ogihara T: In vivo transfection of cis element "decoy" against nuclear factor-κB binding site prevents myocardial infarction. Nat Med (1997) 3(8):894-899.
10. Tomita T, Takeuchi E, Tomita N, Morishita R, Kaneko, Yamamoto K, Nakase T, Seki H, Kato K, Kaneda Y, Ochi T: Suppressed severity of collagen-induced arthritis by in vivo transfection of nuclear factor κB decoy oligodeoxynucleotides as a gene therapy. Arthritis Rheum (1999) 42(12):2532-2542.
11. Tomita N, Horiuchi M, Tomita S, Gibbons GH, Kim JY, Baran D, Dzau VJ: An oligonucleotide decoy for transcription factor E2F inhibits mesangial cell proliferation in vitro. Am J Physiol (1998) 275(2 Pt 2):F278-F284.
12. Tomita N, Morishita R, Lan HY, Yamamoto K, Hashizume M, Notake M, Fujitani B, Mu W, Nikolic-Paterson DJ, Atkins RC, Kaneda Y et al: In vivo administration of a nuclear factor-κB decoy suppressed experimental crescentic glomerulonephritis. J Am Soc Nephrol (2000) 11(7):1244-1252.
13. Tomita N, Morishita R, Tomita S, Gibbons GH, Zhang L, Horiuchi M, Kaneda Y, Higaki J, Ogihara T, Dzau VJ: Transcription factor decoy for NFκB inhibits TNFα-induced cytokine and adhesion molecules expression in vivo. Gene Ther(2000) 7(15):1326-1332.
14. Weintraub SJ, Prater CA, Dean DC: Retinoblastoma protein switches the E2F site from positive to negative element. Nature (1992) 358(6383):259-261.
15. Hiebert SW, Lipp M, Nevins JR: E1A-dependent trans-activation of the human MYC promoter is mediated by the E2F factor. Proc Natl Acad Sci USA (1989) 86(10):3594-3598.
16. Kaneda Y, Iwai K, Uchida T: Increased expression of DNA cointroduced with nuclear protein in adult rat liver. Science (1989) 243(4889):375-378.
17. Kaneda Y, Iwai K, Uchida T: Introduction and expression of the human insulin gone in adult rat liver. J Biol Chem (1989) 264(21):12126-12129.
18. Tomita N, Higaki J, Kaneda Y, Yu H, Morishita R, Mikami H, Ogihara T: Hypertensive rats produced by in vivo introduction of the human renin gene. Circ Res (1993) 73(5):898-905.
19. Kaneda Y, Morishita R, Tomita N: Increased expression of DNA co-introduced with nuclear protein in adult rat liver. J Mol Med (1995) 73(6):289-297.
20. Dzau VJ, Mann MJ, Morishita R, Kaneda Y: Fusigenic viral liposome for gene therapy in cardiovascular diseases. Proc Natl Acad Sci USA (1996) 93(21):11421-11425.
21. Morishita R, Gibbons GH, Pratt RE, Tomita N, Kaneda Y, Ogihara T, Dzau VJ: Autocrine and paracrine effects of atrial natriuretic peptide gene transfer on vascular smooth muscle and endothelial cellular growth. J Clin Invest (1994) 94(2):824-829.
22. Kaneda Y, Saeki Y, Morishita R: Gene therapy using HVJ-liposomes: The best of both worlds? Mol Med Today (1999) 5(7):298-303.
23. Baeuerle PA, Henkel T: Function and activation of NFκB in the immune system. Annu Rev Immunol (1994) 12:141-179.
24. Chow J, Hartley RB, Jagger C, Dilly SA: ICAM-1 expression in renal disease. J Clin Pathol (1992) 45(10):880-884.
25. Floege J, Eng E, Young BA, Johnson RJ: Factors involved in the regulation of mesangial cell proliferation in vitro and in vivo. Kidney Int Suppl (1993) 39:S47-S54.
26. Sterzel RB, Schulze-Lohoff E, Marx M: Cytokines and mesangial cells. Kidney Int Suppl (1993) 39:S26-S31.
27. Egido J, Gomez-Chiarri M, Ortiz A, Bustos C, Alonso J, Gomez-Guerrero C, Gomez-Garre D, Lopez-Armada MJ, Plaza J, Gonzalez E: Role of tumor necrosis factor-α in the pathogenesis of glomerular diseases. Kidney Int Suppl (1993) 39:S59-S64.
28. Herskowitz A, Choi S, Ansari AA, Wesselingh S: Cytokine mRNA expression in postischemic/reperfused myocardium. Am J Pathol (1995) 146(2):419-428.
29. Kukielka GL, Smith CW, LaRosa GJ, Manning AM, Mendoza LH, Daly TJ, Hughes BJ, Youker KA, Hawkins HK, Michael LH: Interleukin-8 gene induction in the myocardium after ischemia and reperfusion in vivo. J Clin Invest (1995) 95(1):89-103.
30. Lenardo MJ, Baltimore D: NFκB: A pleiotropic mediator of inducible and tissue-specific gene control. Cell (1989) 58(2):227-229.
31. Libermann TA, Baltimore D: Activation of interleukin-6 gene expression through the NFκB transcription factor. Mol Cell Biol (1990) 10(5):2327-2334.
32. Satriano J, Schlondorff D: Activation and attenuation of transcription factor NFκB in mouse glomerular mesangial cells in response to tumor necrosis factor-α, immunoglobulin G, and adenosine 3′,5′-cyclic monophosphate. Evidence for involvement of reactive oxygen species. J Clin Invest (1994) 94(4 ):1629-1636.
33. Neish AS, Williams AJ, Palmer HJ, Whitley MZ, Collins T: Functional analysis of the human vascular cell adhesion molecule 1 promoter. J Exp Med (1992) 176(6):1583-1593.
34. Brennan DC, Jevnikar AM, Takei F, Reubin-Kelley VE: Mesangial cell accessory functions: Mediation by intercellular adhesion molecule-1. Kidney Int (1990) 38(6):1039-1046.
35. Tomita N, Higaki J, Morishita R, Kato K, Mikami H, Kaneda Y, Ogihara T: Direct in vivo gone introduction into rat kidney. Biochem Biophys
36. Tomita N, Kim J, Gibbons GH, Baran D, Ogbom M, Stahl RAK, Tomita S, Zhang L, Kaneda Y, Dzau VJ: In vivo gene therapy of anti-thy 1 nephritis using E2F decoy oligonucleotide. J Am Soc Nephrol (1994) 6:887.
37. Noronha IL, Kruger C, Andrassy K, Ritz E, Waldherr R: In situ production of TNFα, IL-1Β and IL-2R in ANCA-positive glomerulonephritis. Kidney Int (1993) 43(3):682-692.
38. Niemir ZI, Stein H, Dworacki G, Mundel P, Koehl N, Koch B, Autschbach F, Andrassy K, Ritz E, Waldherr R, Otto HF: Podocytes are the major source of IL-1α and IL-1Β in human glomerulonephritides. Kidney Int (1997) 52(2):393-403.
39. Tomita T, Hashimoto H, Tomita N, Morishita R, Lee SB, Hayashida K, Nakamura N, Yonenobu K, Kaneda Y, Ochi T: In vivo direct gene transfer Into articular cartilage by intraarticular injection mediated by HVJ (Sendal virus) and liposomes. Arthritis Rheum (1997) 40(5):901-906.
40. Moon IJ, Choi K, Choi YK, Kim JE, Lee Y, Schreiber AD, Park JG: Potent growth inhibition of leukemic cells by novel ribbon-type antisense oligonucleotides to c-myb1. J Biol Chem (2000) 275(7):4647-4653.
41. Hosoya T, Takeuchi H, Kanesaka Y, Yamakawa H, Miyano-Kurosaki N, Takai K, Yamamoto N, Takaku H: Sequence-specific inhibition of a transcription factor by circular dumb-bell DNA oligonucleotides. FEBS Lett (1999) 461(3):136-140.
42. Gao WY, Han FS, Storm C, Egan W, Cheng YC: Phosphorothioate oligonucleotides are inhibitors of human DNA polymerase and RNase H: Implications for antisense technology. Mol Pharmacol (1992) 41(2):223:229.
43. Brown DA, Kang SH, Gryaznov SM, DeDionisio L, Heidenreich O, Sullivian S, Xu X, Nerenberg MI: Effect of phosphorothioate modification of oligodeoxynucleotides on specific protein binding. J Biol Chem (1994) 269(43):26801-26805.
44. Burgress TL, Fisher EF, Ross SL, Bready JV, Qian YX, Baywitch LA, Cohen AM, Herrera CJ, Hu SS, Kramer TB, Lott FD et al: The antiproliferative activity of c-Myb and c-Myc antisense oligonucleotides in smooth muscle cells is caused by a nonantisense mechanism. Proc Natl Acad Sci USA (1995) 92(9):4051-4055.
45. Chu BCF, Orgel LE: The stability of different forms of double-stranded decoy DNA in serum and nuclear extracts. Nucleic Acids Res (1992) 20(21):5857-5858.
46. Abe T, Takai K, Nakada S, Yokota T, Takaku H: Specific inhibition of influenza virus RNA polymerase and nucleoprotein gene expression by circular dumb-bell RNA/DNA chimeric oligonucleotides containing antisense phosphodiester oligonucleotides. FEBS Lett (1998) 425(1):91-96.
47. Ahn JD, Morishita R, Kaneda Y, Lee SJ, Kwon KY, Choi SY, Lee KU, Park JY, Moon IJ, Park JY, Yoshizumi M et al: Inhibitory effects of novel AP-1 decoy oligodeoxynucleotides on vascular smooth muscle cell proliferation in vitro and neointimal formation in vivo. Circ Res (2002) 90(12):1325-1332.
48. Ahn JD, Morishita R, Kaneda Y, Kim HS, Chang YC, Lee KU, Park JY, Kim YH, Lee IK: Novel E2F decoy oligodeoxynucleotides inhibit in vitro vascular smooth muscle cell proliferation and in vivo neointimal hyperplasia. Gene Ther (2002) 9(24):1682-1692.
49. Anderson WF: Human gene therapy. Science (1992) 256(5058):808-813.
50. Miller AD: Human gene therapy comes of age. Nature (1992) 357 (6378):455-460.
51. Mann MJ, Whittemore AD, Donaldson MC, Belkin M, Conte MS, Polak JF, Orav EJ, Ehsan A, Dell'Acqua G, Dzau VJ: Ex-vivo gene therapy of human vascular bypass grafts with E2F decoy: The PREVENT single-centre, randomised, controlled trial. Lancet (1999) 345(9189):1493-1498.